Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias

INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and...

Descripción completa

Detalles Bibliográficos
Autores: Doecke, J.D.|||0000-0003-2863-0293, Bellomo, G., Vermunt, L., Alcolea, Daniel|||0000-0002-3819-3245, Halbgebauer, S., in 't Veld, S., Mattsson-Carlgren, N., Veverova, K., Fowler, C.J., Boonkamp, L., Houtkamp, I.M., Koel-Simmerlink, M., Verberk, I.M.W., Gaetani, L., Toja, A., Wojdała, A.L., Fortea, Juan|||0000-0002-1340-638X, Pijnenburg, Y., Lemstra, A., van der Flier, W., Hort, J., Hansson, Oskar|||0000-0001-8467-7286, Parnetti, Lucilla|||0000-0001-5722-3967, Masters, C.L., Lleó, Alberto|||0000-0002-2568-5478, González-Escalante, Armand, Contador, José, Suárez-Calvet, Marc|||0000-0002-2993-569X, Fernández-Lebrero, Aida|||0000-0002-2097-4430, Puig-Pijoan, Albert|||0000-0002-9848-3711, Ortiz-Romero, Paula|||0000-0002-6378-6763, Jiménez-Moyano, Esther|||0000-0002-0005-6544, Minguillón, Carolina, Campo Milán, Marta del|||0000-0003-2808-3699, Teunissen, Charlotte E.|||0000-0002-4061-0837, Otto, M.|||0000-0003-4273-4267
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:322771
Acceso en línea:https://ddd.uab.cat/record/322771
https://dx.doi.org/urn:doi:10.1002/alz.14573
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
Amyloid beta
Dementia with Lewy bodies
Frontotemporal dementia
Plasma biomarkers
Descripción
Sumario:INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. RESULTS: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. DISCUSSION: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.

Similares en LA Referencia